New combo therapy aims to control High-Risk endometrial cancer
NCT ID NCT03932409
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study tests whether adding the immunotherapy drug pembrolizumab to standard radiation and chemotherapy can help control high-risk endometrial cancer after surgery. About 45 participants who have had a hysterectomy will receive radiation to the vagina, followed by three cycles of pembrolizumab plus chemo. The main goal is to see if patients can complete all three cycles of the combination treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
LSU Health New Orleans
New Orleans, Louisiana, 70112, United States
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
Conditions
Explore the condition pages connected to this study.